Notice2022-20048
Foreign-Trade Zone (FTZ) 27-Boston, Massachusetts, Notification of Proposed Production Activity, Wyeth Pharmaceuticals, LLC (Shingles and Flu Vaccines), Andover, Massachusetts
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
September 16, 2022
Issuing agencies
Commerce DepartmentForeign-Trade Zones Board
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 179 (Friday, September 16, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 179 (Friday, September 16, 2022)]
[Notices]
[Page 56928]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-20048]
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[B-43-2022]
Foreign-Trade Zone (FTZ) 27--Boston, Massachusetts, Notification
of Proposed Production Activity, Wyeth Pharmaceuticals, LLC (Shingles
and Flu Vaccines), Andover, Massachusetts
Wyeth Pharmaceuticals, LLC (Wyeth) submitted a notification of
proposed production activity to the FTZ Board (the Board) for its
facility in Andover, Massachusetts within Subzone 27R. The notification
conforming to the requirements of the Board's regulations (15 CFR
400.22) was received on September 8, 2022.
Pursuant to 15 CFR 400.14(b), FTZ production activity would be
limited to the specific foreign-status material(s)/component(s) and
specific finished product(s) described in the submitted notification
(summarized below) and subsequently authorized by the Board. The
benefits that may stem from conducting production activity under FTZ
procedures are explained in the background section of the Board's
website--accessible via <a href="http://www.trade.gov/ftz">www.trade.gov/ftz</a>. The proposed finished
product(s) and material(s)/component(s) would be added to the
production authority that the Board previously approved for the
operation, as reflected on the Board's website.
The proposed finished products include mRNA Varicella-Zoster Virus
Shingles Vaccine and saRNA Flu Vaccine (duty-free).
The proposed foreign-status material/component is N1-Methyl-
Pseudouridine-5'-Triphosphate (duty rate, 6.5%). The request indicates
that the material/component is subject to duties under Section 301 of
the Trade Act of 1974 (section 301), depending on the country of
origin. The applicable Section 301 decisions require subject
merchandise to be admitted to FTZs in privileged foreign status (19 CFR
146.41).
Public comment is invited from interested parties. Submissions
shall be addressed to the Board's Executive Secretary and sent to:
<a href="/cdn-cgi/l/email-protection#6e081a142e1a1c0f0a0b40090118"><span class="__cf_email__" data-cfemail="6600121c26121407020348010910">[email protected]</span></a>. The closing period for their receipt is October 26,
2022.
A copy of the notification will be available for public inspection
in the ``Online FTZ Information System'' section of the Board's
website.
For further information, contact Diane Finver at
<a href="/cdn-cgi/l/email-protection#8acee3ebe4efa4cce3e4fceff8cafef8ebeeefa4ede5fc"><span class="__cf_email__" data-cfemail="612508000f044f27080f1704132115130005044f060e17">[email protected]</span></a>.
Dated: September 12, 2022.
Christopher Kemp,
Acting Executive Secretary.
[FR Doc. 2022-20048 Filed 9-15-22; 8:45 am]
BILLING CODE 3510-DS-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on September 16, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.